Results 81 to 90 of about 18,762 (211)

Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective

Saudi Pharmaceutical Journal
Objectives: To perform a budget impact analysis (BIA) of the adoption of baricitinib for the management of alopecia areata (AA) by a Saudi public sector payer.
A. Alshahrani, S. Al-Aqeel, M. Alshahrani, S. Alqahtani, S.T. Alhawwashi, M.S. Al-Nasser, M. Zaitoun   +6 more
doaj   +1 more source

The safety and immunogenicity of live Zoster Vaccination in patients with rheumatoid arthritis before starting Tofacitinib: a randomized phase II trial [PDF]

, 2017
Objective Patients with rheumatoid arthritis (RA) are at increased risk of herpes zoster, and vaccination is recommended for patients ages 50 years and older, prior to starting treatment with biologic agents or tofacitinib.
Aletaha, Aletaha, Assen, Burmester, Curtis, Fleischmann, Fleischmann, Friedman, Hales, Harpaz, Heijde, Jung, Kremer, Lee, Levin, Levin, Oxman, Perry, Pierson, Rubin, Ruderman, Schmader, Singh, Singh, Smolen, Vollenhoven, Winthrop, Wollenhaupt, Wollenhaupt, Yun   +29 more
core   +2 more sources

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis [PDF]

, 2019
Objective: To evaluate clinical outcomes in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, during a phase III programme.Methods: In phase III RA-BEAM, patients were randomised 3:3:2 to placebo ...
De Bono, S, Fautrel, B, Issa, M, Keystone, E, Ortmann, R, Patel, H, Rooney, T, Tanaka, Y, Taylor, Peter, Zhu, B   +9 more
core   +2 more sources

Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor‐Modulating Agent in the Treatment of Atopic Dermatitis

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory dermatitis underpinned by Type 2 inflammation driven by cytokines such as IL‐4 and IL‐13. It is characterized by skin barrier dysfunction, Th2 immune deviation, and pruritus. While biologics and oral Janus kinase (JAK) inhibitors demonstrate high therapeutic efficacy by targeting cytokines that ...
Gaku Tsuji, Yoko Fuyuno, Koji Kawamura, Ayako Yumine, Masaki Takemura, Yasutaka Mitamura, Kazuhiko Yamamura, Takeshi Nakahara   +7 more
wiley   +1 more source

Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro

Journal of Neuroinflammation, 2019
Background Since HIV-associated neurocognitive disorders (HANDs) occur in up to half of HIV-positive individuals, even with combined antiretroviral therapy (cART), adjunctive therapies are needed.
Christina Gavegnano, Woldeab B. Haile, Selwyn Hurwitz, Sijia Tao, Yong Jiang, Raymond F. Schinazi, William R. Tyor   +6 more
doaj   +1 more source

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Baricitinib [PDF]

Reactions Weekly, 2020
  +5 more sources

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach [PDF]

, 2017
Background: This analysis assessed, on a group level, whether there is a long-term advantage for early RA patients treated with adalimumab (ADA) + MTX vs those initially treated with placebo (PBO) + MTX who either responded to therapy or added ADA ...
Adebajo, Adewale O., Adeleke, Gbadebo, Agarwal, Sunil, Alten, Rieke, Anderson, Jaclyn, Appleton, Louise H., Baker, Jonathan, Barton, Anne, Bayley, Rachel, Beattie, Scott, Berclaz, Pierre-Yves, Bissell, Lesley-Anne, Bowes, John, Brown, Matthew A., Buckley, Christopher, Buckley, Christopher, Cao, Dandan, Charles, Peter, Chinoy, Hector, Chowdhury, Muslima, Ciani, Barbara, Citera, Gustavo, Cohen, Carla J., Conaghan, Philip, Das, Sudipto, Davies, Holly, Dikranian, Ara H., Dougados, Maxime, Dougherty, Brian, Drescher, Edit, Edwards, Steven W., Elewaut, Dirk, Emery, Paul, Emery, Paul, Emery, Paul, Evans, David, Fidelus-Gort, Rosalind, Filer, Andrew, Fisher, Benjamin, FitzGerald, Oliver, Fitzgerald, Oliver, Fitzpatrick, Martin A., Fleischmann, Roy, Fleischmann, Roy, Florentinus, Stefan, Gabay, Cem, Genovese, Mark, Giles, Jon T., Gomez-Reino, Juan J., Goupille, Philippe, Green, Jennifer, Hamann, Philip, Hamilton, Bart, Haroon, Muhammad, Haroon, Muhammad, Harper, Lorraine, Harris, Juliette, Harrow, Ian, Hawtree, Sarah, He, Wen, Heward, James, Hu, ChiaChi, Hunt, Laura, Hyde, Craig L., Isaacs, John, Jani, Meghna, Jin, Xin, John, Sally, Karaderi, Tugce, Kavanaugh, Arthur, Kavanaugh, Arthur, Kavanaugh, Arthur, Keidel, Sarah, Keystone, Edward C., Khetan, Sachin, Kitas, George D., Kite, Kerry A., Klearman, Micki, Kupper, Hartmut, Lee, Chin, Lindsay, Mark A., Litherland, Gary J., Livshits, Gregory, Luchi, Monica, Lugli, Elena, Macfarlane, Gary J., MacGregor, Alexander, Macias, William, Macphie, Elizabeth, Maksymowych, Walter P., Malarstig, Anders, Maldonado, Michael A., McEwen, Robert, McGettrick, Helen M., McGonagle, Dennis, McHugh, Neil, McLoughlin, Yokemei, McMahon, Stephen B., Mease, Philip, Memari, Yasin, Mikuls, Ted, Mirjafari, Hoda, Moore, Sarah, Moots, Robert, Morgan, Ann W., Morrow, Fiona, Murphy, Conor, Musselman, David, Muthana, Munitta, Nam, Jacqueline L., Nash, Gerard, O'Rourke, Michael, Orozco, Gisela, Pangan, Aileen L., Pangan, Aileen L., Pangan, Aileen L., Patel, Ketan, Paul Wordsworth, B., Plant, Darren, Potempa, Jan, Preeti, Shah, Quirke, Anne-Marie, Rakieh, Chadi, Ramasamy, Pathma, Rao, Chan, Rathmann, Suchitrita, Rathmann, Suchitrita, Rathmann, Suchitrita S., Raza, Karim, Rowan, Andrew D., Schiff, Michael H., Schlichting, Douglas, Scollen, Serena, Shi, Yujian, Shin, So-Youn, Sidders, Benjamin, Siebert, Stefan, Sieper, Joachim, Sieper, Joachim, Sieper, Joachim, Smith, Jacqueline P., Smolen, Josef, Soranzo, Nicole, Spector, Tim, Spector, Tim D., Stephens, Joel L., Stevens, Randall, Surdulescu, Gabriela, Taylor, Peter, Tazzyman, Simon, Thiele, Geoffrey, Thomas, Huw B., Valente, Robert, Van den Bosch, Filip, van der Heijde, Desiree, van der Heijde, Desiree, van der Heijde, Desiree, van der Heijde, Desiree, van Vollenhoven, Ronald F., van Vollenhoven, Ronald F., Venables, Patrick, Villeneuve, Edith, Wakefield, Richard J., Wang, Jun, Wegner, Natalia, Weinblatt, Michael E., Williams, Frances M., Williams, Frances M., Williams, Julie, Wilson, Anthony G., Wilson, Gerry, Winchester, Robert, Wollenhaupt, Jurgen, Wright, Helen L., Yang, Peiming, Young, Stephen P., Young, Stephen P., Ytterberg, Jimmy, Zhang, Baohong, Zhao, Cathy, Ziemek, Daniel   +180 more
core  

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis [PDF]

, 2019
Objective To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active ...
Burmester, GR, Cardoso, A, Gonzalez-Gay, MA, Issa, M, Rooney, TP, Saifan, C, Salinas, CA, Takeuchi, T, Taylor, Peter, Walls, CD, Weinblatt, ME, Witt, S, Zhang, X   +12 more
core   +3 more sources

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source